Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
Date:9/27/2010

PARSIPPANY, N.J., Sept. 27 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette® and NicoDerm® CQ®, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.(1) GSK Consumer Healthcare agrees that these products should not be used as an alternative to cigarettes or for smoking cessation due to the potential negative health consequences and their impact on smoking behavior. 

The AHA statement is important because the U.S. Food and Drug Administration (FDA) has just finished accepting comments from the public on how FDA should regulate certain smokeless tobacco products.  GSK Consumer Healthcare submitted a comment to the FDA on the potential public health impact of oral dissolvable tobacco products.  In our submission, GSK Consumer Healthcare called for oral dissolvable tobacco products to be withdrawn from the market until their sponsors can demonstrate to FDA that their marketing is appropriate for the protection of public health.

The AHA policy statement, notes that smokeless tobacco products are not safe alternatives to smoking and are associated with heart attack, stroke and certain cancers.(1)  Also, due to the marketing of these products, smokeless tobacco products may also initiate further tobacco use and perpetuate smoking.(1) 

Tobacco use, including smokeless tobacco, is the largest cause of preventable death and disease in the world.(2)  More than 400,000 Americans die every year from tobacco-related disease.(2)  The only proven way to reduce these health consequences is to stop using tobacco completely.  Smokeless tobacco products are currently being marketed without clear evidence of their safety.

NRT products alternatively, have helped millions of people around the world quit smoking and, as a result, have significantly reduced their exposure to the risks of cancer and other smoking-related diseases.(3)  GlaxoSmithKline Consumer Healthcare believes that before considering a potential role for oral dissolvable tobacco products in reducing the adverse health effects of smoking, there are significant opportunities to enhance the impact of existing smoking cessation aids, including expanding access to and use of NRT products. While the FDA is the final authority on the labeling of NRT products sold in the U.S., GSK Consumer Healthcare is committed to continuing to work with medical and clinical experts, and the FDA, to ensure that consumers have the best possible chance to quit smoking.

Quitting smoking is the single most important step smokers can take to improve their health – and it's also one of the most difficult.  By developing innovative new products and support systems to improve the quit experience, and helping to make the products as accessible as possible, GSK Consumer Healthcare works to inspire and enable every smoker to quit for good.

  1. Piano, et al. Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment. A Policy Statement From the American Heart Association. Circulation published online Sep 13, 2010. Available at http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181f432c3v1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=smokeless+tobacco&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT.
  2. Centers for Disease Control and Prevention. Targeting Tobacco Use: The Nation's Leading Cause of Preventable Death. Available at http://www.cdc.gov/nccdphp/publications/aag/osh.htm.
  3. GSK data on file.


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
2. Statement from CHPA on Todays FDA Advisory Committee Meeting on Dextromethorphan
3. Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
4. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
5. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
6. NCPA Statement on CVS Caremark-Aetna Agreement
7. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
8. Dendreon Statement on CMS National Coverage Analysis
9. NORD Calls for Statement of Policy on Orphan Drug Development
10. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
11. Alexza Pharmaceuticals Files Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):